BACKGROUNDS/AIMS: Heme oxygenase-1 (HO-1) has been shown to protect against fibrotic proliferation and apoptosis in several models of renal damage. The purpose of this study was to evaluate the impact of a treatment with the HO-1 inducer hemin on the progression of chronic kidney disease in nephrectomized rats versus the AT1 receptor antagonist losartan. METHODS: The rats underwent 5/6 renal ablation and after the procedure received either losartan (20 mg/kg/day; n = 9), hemin (50 mg/kg/twice a week; n = 8) or vehicle (n = 8) over a 12-week period. At week 12, blood pressure was measured, urine, blood and remnant kidney were collected for biochemical (proteinuria, urea, creatinine) and histopathological (degrees of glomerulosclerosis and tubular atrophy) analysis. The expressions of HO-1, bone morphogenic protein 7 (BMP-7) and TGF-beta were assessed by immunochemistry, and the level of the apoptosis marker protein caspase-3 by Western blot, on the remnant kidney. RESULTS: Hemin significantly reduced blood pressure, proteinuria, inhibited the expression of TGF-beta and caspase-3 protein and increased BMP-7 expression protein. Hemin-treated rats had lower glomerulosclerosis and tubular atrophy indexes than controls. CONCLUSION: Hemin treatment attenuates the progression of chronic kidney disease and appears more efficient than losartan in our rat model hypothetically because of the impact of hemin on the renal expression of BMP-7. Copyright 2009 S. Karger AG, Basel.
BACKGROUNDS/AIMS: Heme oxygenase-1 (HO-1) has been shown to protect against fibrotic proliferation and apoptosis in several models of renal damage. The purpose of this study was to evaluate the impact of a treatment with the HO-1 inducer hemin on the progression of chronic kidney disease in nephrectomized rats versus the AT1 receptor antagonist losartan. METHODS: The rats underwent 5/6 renal ablation and after the procedure received either losartan (20 mg/kg/day; n = 9), hemin (50 mg/kg/twice a week; n = 8) or vehicle (n = 8) over a 12-week period. At week 12, blood pressure was measured, urine, blood and remnant kidney were collected for biochemical (proteinuria, urea, creatinine) and histopathological (degrees of glomerulosclerosis and tubular atrophy) analysis. The expressions of HO-1, bone morphogenic protein 7 (BMP-7) and TGF-beta were assessed by immunochemistry, and the level of the apoptosis marker protein caspase-3 by Western blot, on the remnant kidney. RESULTS:Hemin significantly reduced blood pressure, proteinuria, inhibited the expression of TGF-beta and caspase-3 protein and increased BMP-7 expression protein. Hemin-treated rats had lower glomerulosclerosis and tubular atrophy indexes than controls. CONCLUSION:Hemin treatment attenuates the progression of chronic kidney disease and appears more efficient than losartan in our rat model hypothetically because of the impact of hemin on the renal expression of BMP-7. Copyright 2009 S. Karger AG, Basel.
Authors: Matheus Correa-Costa; Patricia Semedo; Ana Paula F S Monteiro; Reinaldo C Silva; Rafael L Pereira; Giselle M Gonçalves; Georgia Daniela Marcusso Marques; Marcos A Cenedeze; Ana C G Faleiros; Alexandre C Keller; Maria H M Shimizu; Antônio C Seguro; Marlene A Reis; Alvaro Pacheco-Silva; Niels O S Câmara Journal: PLoS One Date: 2010-12-13 Impact factor: 3.240
Authors: Gladys O Latunde-Dada; Abas H Laftah; Patarabutr Masaratana; Andrew T McKie; Robert J Simpson Journal: Front Pharmacol Date: 2014-06-04 Impact factor: 5.810
Authors: Ellen On Ptilovanciv; Gabryelle S Fernandes; Luciana C Teixeira; Luciana A Reis; Edson A Pessoa; Marcia B Convento; Manuel J Simões; Guilherme A Albertoni; Nestor Schor; Fernanda T Borges Journal: Diabetol Metab Syndr Date: 2013-01-16 Impact factor: 3.320